Loading...
Disclaimer: Informational only — not medical advice. AI hypotheses are not clinically validated. Medic Oath is for informational and educational purposes only — not medical advice. AI-generated hypotheses have not been clinically validated. Always consult a qualified healthcare professional. Privacy · Terms
Cranio-cerebello-cardiac (3C) syndrome is a rare multiple congenital anomalies syndrome characterized by craniofacial (prominent occiput and forehead, hypertelorism, ocular coloboma, cleft palate), cerebellar (Dandy-Walker malformation, cerebellar vermis hypoplasia) and cardiac (tetralogy of Fallot, atrial and ventricular septal defects) anomalies.
The standardized Kampo formula TU-100 contains hydroxy-α-sanshool from Zanthoxylum fruit, which activates TRPA1 and TRPV1 channels in enteric neurons, enhancing acetylcholine release and improving gastrointestinal motility. Gingerols and shogaols synergistically modulate 5-HT3 receptors to reduce nausea and accelerate gastric emptying.
Baicalein, the primary flavonoid from Scutellaria baicalensis, selectively inhibits BMP2/4 signaling through direct binding to BMP receptors ALK2 and ALK3, preventing premature osteoblast differentiation. The compound also upregulates TWIST1 expression via PI3K/AKT pathway activation, maintaining suture patency during cranial development.
Mesembrine and mesembrenone from Sceletium tortuosum selectively inhibit phosphodiesterase-4 (PDE4), increasing cAMP levels and enhancing CREB-mediated neuroplasticity. These alkaloids also inhibit serotonin reuptake with IC50 of 4.3 μM, providing dual anxiolytic mechanisms without benzodiazepine dependence risks.
Metformin activates AMPK to suppress mTORC1 signaling while rapamycin directly inhibits mTORC1, creating synergistic growth regulation. This dual inhibition reduces IGF-1 pathway hyperactivation and normalizes chondrocyte proliferation in growth plates, addressing both overgrowth and metabolic dysregulation characteristic of 3C syndrome.
Withanoside VI, a unique withanolide glycoside from Withania somnifera roots, acts as a positive allosteric modulator of GABA-A receptors, specifically binding to the α2β3γ2 subtype. This enhances inhibitory neurotransmission and reduces seizure susceptibility while promoting dendritic spine formation through CREB phosphorylation.
Lenalidomide binds cereblon (CRBN) E3 ubiquitin ligase, promoting targeted degradation of IKZF1 and CK1α proteins that regulate neural crest cell migration and differentiation. This mechanism could correct aberrant transcriptional programs affecting craniofacial development in 3C syndrome patients.